celastrol has been researched along with carboplatin in 1 studies
| Studies (celastrol) | Trials (celastrol) | Recent Studies (post-2010) (celastrol) | Studies (carboplatin) | Trials (carboplatin) | Recent Studies (post-2010) (carboplatin) |
|---|---|---|---|---|---|
| 885 | 1 | 741 | 12,895 | 4,001 | 5,244 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Benedict, B; Hulleman, E; Kaspers, GJL; Koster, J; Meel, MH; Metselaar, DS; Waranecki, P | 1 |
1 other study(ies) available for celastrol and carboplatin
| Article | Year |
|---|---|
Celastrol-induced degradation of FANCD2 sensitizes pediatric high-grade gliomas to the DNA-crosslinking agent carboplatin.
Topics: Adolescent; Animals; Carboplatin; Cell Line, Tumor; Cell Survival; Child; Child, Preschool; Cross-Linking Reagents; Disease Models, Animal; DNA Damage; Drug Resistance, Neoplasm; Fanconi Anemia Complementation Group D2 Protein; Female; Glioma; Humans; Male; Mice; Neoplasm Grading; Pentacyclic Triterpenes; Proteolysis; Triterpenes; Xenograft Model Antitumor Assays | 2019 |